UCB Japan, Daiichi Pharmaceutical to Reinforce Their Collaboration for Antiallergic Agent Zyrtec.Tokyo, Japan, Aug 2, 2005 - (JCNN JCNN Japan Corporate News Network ) - UCB UCB - University of California at Berkeley Japan (UCBJ) and Daiichi Pharmaceutical have agreed to form a long-term alliance in sales of Zyrtec Tablet 5 and Zyrtec Tablet 10, UCBJ's proprietary antiallergic an·ti·al·ler·gic adj. Preventing or relieving allergies. antiallergic adjective Countering allergy or an allergic state agent. Under the terms of the agreement, Daiichi Pharmaceutical will retain the right to co-promote the product with Sankyo until September when their joint holding company Daiichi Sankyo is established. An orally active and selective H1-receptor antagonist currently prescribed in over 100 countries worldwide, Zyrtec shows significant antiallergic effects with a once-a-day dosage. Daiichi Pharmaceutical and GlaxoSmithKline has been distributing the agent in Japan since 1998. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion